26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nanoparticles in the clinic: An update

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

          TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study

            Significance Prostate cancer is the most common nonskin cancer in the United States, where approximately 1 in 9 men will be diagnosed in their lifetime. The prostate is near several vital structures, such as the urethra and neurovascular bundle, and whole gland treatments for prostate cancer can disrupt normal urinary, bowel, and sexual functioning. Here we report the initial results of a clinical trial for nanoparticle-based photothermal cancer therapy. The trial was designed to perform ultrafocal photothermal ablation of cancerous tumors within the prostate. Gold-silica nanoparticles designed to absorb near-infrared light at wavelengths of high tissue transparency provide a highly localized light-based strategy for the treatment of prostate cancer, with substantially reduced risks for deleterious treatment-related side effects.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

                Bookmark

                Author and article information

                Contributors
                aanselmo@email.unc.edu
                mitragotri@seas.harvard.edu
                Journal
                Bioeng Transl Med
                Bioeng Transl Med
                10.1002/(ISSN)2380-6761
                BTM2
                Bioengineering & Translational Medicine
                John Wiley & Sons, Inc. (Hoboken, USA )
                2380-6761
                05 September 2019
                September 2019
                : 4
                : 3 , ECI Nanotechnology in Medicine II (Part 2) ( doiID: 10.1002/btm2.v4.3 )
                : e10143
                Affiliations
                [ 1 ] Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina
                [ 2 ] John A Paulson School of Engineering and Applied Sciences Harvard University, Wyss Institute of Biologically Inspired Engineering Cambridge Massachusetts
                Author notes
                [*] [* ] Correspondence

                Aaron C. Anselmo, Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

                Email: aanselmo@ 123456email.unc.edu

                Samir Mitragotri, John A Paulson School of Engineering and Applied Sciences, Harvard University, Wyss Institute of Biologically Inspired Engineering, Cambridge, MA 02138.

                Email: mitragotri@ 123456seas.harvard.edu

                Author information
                https://orcid.org/0000-0003-3290-7857
                https://orcid.org/0000-0002-2459-8305
                Article
                BTM210143
                10.1002/btm2.10143
                6764803
                31572799
                7b9232b0-e565-442d-9322-8f30b68f3f34
                © 2019 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 05 August 2019
                : 22 August 2019
                : 23 August 2019
                Page count
                Figures: 0, Tables: 3, Pages: 16, Words: 6475
                Funding
                Funded by: National Institutes of Health NCI
                Award ID: 5U54CA198999‐04
                Funded by: National Institutes of Health
                Award ID: 1R01HL143806‐01
                Categories
                Review
                Reviews
                Custom metadata
                2.0
                btm210143
                September 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.9 mode:remove_FC converted:27.09.2019

                clinic,clinical translation,clinical trials,drug delivery,nanomedicine,nanoparticles,translational medicine

                Comments

                Comment on this article